Biology Reference
In-Depth Information
Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey Jr RT, Falloon J, Polis MA, Walker RE,
Stevens R, Salzman NP, et al. 1995. Increases in CD4 T lymphocytes with intermittent courses
of interleukin-2 in patients with human immunode®ciency virus infection. A preliminary study
[see comments]. N Engl J Med 332: 567±575.
Kovacs JA, Vogel S, Albert JM, Falloon J, Davey Jr RT, Walker RE, Polis MA, Spooner K,
Metcalf JA, Baseler M, Fyfe G, Lane HC. 1996. Controlled trial of interleukin-2 infusions in
patients infected with the human immunode®ciency virus [see comments]. N Engl J Med 335:
1350±1356.
Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. 1988. Cytokines alter pro-
duction of HIV-1 from primary mononuclear phagocytes. Science 241: 1673±1675.
Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler
M, Salzman N, Manischewitz J, Quinnan G, Masur H, Fauci AS. 1988. Anti-retroviral e¨ects
of interferon-a in AIDS-associated Kaposi's sarcoma. Lancet ii: 1218±1222.
Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, Cerletti N, Shipman R,
Bilbe G, McMaster G. 1991. In vitro e¨ect of transforming growth factor-b on progression of
HIV-1 infection in primary mononuclear phagocytes. J Immunol 147: 1201±1207.
Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, Cerletti N, Shipman R,
Bilbe G, McMaster G. 1992. The replicative restriction of lymphocytotropic isolates of HIV-1 in
macrophages is overcome by TGF-beta. AIDS Res Hum Retroviruses 8: 505±511.
Maciaszek JW, Parada NA, Cruikshank WW, Center DM, Kornfeld H, Viglianti GA. 1997. IL-16
represses HIV-1 promoter activity. J Immunol 158: 5±8.
Mackewicz CE, Patterson BK, Lee SA, Levy JA. 2000. CD8() cell noncytotoxic anti-human im-
munode®ciency virus response inhibits expression of viral RNA but not reverse transcription or
provirus integration. J Gen Virol 81: 1261±1264.
Maggi E, Mazzetti M, Ravina A, Annunziato F, de Carli M, Piccinni MP, Manetti R, Carbonari
M, Pesce AM, del Prete G, Romagnani S. 1994. Ability of HIV to promote a TH1 to TH0 shift
and to replicate preferentially in TH2 and TH0 cells [see comments]. Science 265: 244±248.
McManus CM, Brosnan CF, Berman JW. 1998. Cytokine induction of MIP-1 alpha and MIP-1
beta in human fetal microglia. J Immunol 160: 1449±1455.
Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1
infection predicted by the quantity of virus in the plasma. Science 272: 1167±1170.
Minami Y, Kono T, Miyazaki T, Taniguchi T. 1993. The IL-2 receptor complex: its structure,
function, and target genes. Annu Rev Immunol 11: 245±268.
Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, Baseler M, Ehler LA, Liu S, Davey
Jr RT, Mican JA, Fauci AS. 2000. B cells of HIV-1-infected patients bind virions through
CD21-complement interactions and transmit infectious virus to activated T cells [In Process
Citation]. J Exp Med 192: 637±646.
Monnet C, Laune D, Laroche-Traineau J, Biard-Piechaczyk M, Briant L, Bes C, Pugniere M, Mani
JC, Pau B, Cerutti M, Devauchelle G, Devaux C, Granier C, Chardes T. 1999. Synthetic pep-
tides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and
inhibit HIV-1 promoter activation in virus-infected cells. J Biol Chem 274: 3789±3796.
Montaner LJ, Doyle AG, Collin M, Georges H, James W, Minty A, Caput D, Ferrara P, Gordon
S. 1993. Interleukin 13 inhibits human immunode®ciency virus type 1 production in primary
blood-derived human macrophages in vitro. J Exp Med 178: 743±747.
Montaner LJ, Bailer RT, Gordon S. 1997. IL-13 acts on macrophages to block the completion of
reverse transcription, inhibit virus production, and reduce virus infectivity. J Leukoc Biol 62:
126±132.
Montano MA, Nixon CP, Ndung'u T, Bussmann H, Novitsky VA, Dickman D, Essex M. 2000.
Elevated tumor necrosis factor-alpha activation of human immunode®ciency virus type 1 sub-
type C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J Infect
Dis 181: 76±81.
